The effect of the calcium antagonist, isradipine, on working capacity, pulmonary function, morbidity and survival rate in patients with severe chronic obstructive pulmonary disease (COPD): a randomized, double-blind, placebo-controlled study

No Effect of the Calcium Antagonist, Isr

No Effect of the Calcium Antagonist, Isradipine, on Plasma Catecholamines in Irreversible Chronic Obstructive Pulmonary Disease (COPD). A Randomized, Double-blind, Placebo-controlled Study

✍ Niels A. Graudal; Anders M. Galløe; Inger Plum; Nils Milman; Jesper O. Clausen 📂 Article 📅 1995 🏛 Elsevier 🌐 English ⚖ 243 KB

SUMMARY: Calcium antagonists have been claimed to decrease the pulmonary artery pressure and increase oxygen uptake and cardiac output in patients with chronic obstructive pulmonary disease (COPD). This should tend to decrease the plasma levels of catecholamines. The purpose of the present study was